208 related articles for article (PubMed ID: 36774883)
1. Metabolomic and transcriptomic response to imatinib treatment of gastrointestinal stromal tumour in xenograft-bearing mice.
Macioszek S; Dudzik D; Bartoszewski R; Stokowy T; Lambrechts D; Boeckx B; Wozniak A; Schöffski P; Markuszewski MJ
Transl Oncol; 2023 Apr; 30():101632. PubMed ID: 36774883
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
3. Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.
Van Looy T; Gebreyohannes YK; Wozniak A; Cornillie J; Wellens J; Li H; Vanleeuw U; Floris G; Debiec-Rychter M; Sciot R; Schöffski P
Clin Sarcoma Res; 2014; 4():10. PubMed ID: 25132955
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of multiple protein kinase activities associated with secondary imatinib resistance in gastrointestinal stromal tumors as revealed by quantitative phosphoproteome analysis.
Nagata K; Kawakami T; Kurata Y; Kimura Y; Suzuki Y; Nagata T; Sakuma Y; Miyagi Y; Hirano H
J Proteomics; 2015 Feb; 115():132-42. PubMed ID: 25554490
[TBL] [Abstract][Full Text] [Related]
5. Integrated transcriptomic and metabolomic profiling reveals dysregulation of purine metabolism during the acute phase of spinal cord injury in rats.
Zeng Z; Li M; Jiang Z; Lan Y; Chen L; Chen Y; Li H; Hui J; Zhang L; Hu X; Xia H
Front Neurosci; 2022; 16():1066528. PubMed ID: 36507345
[TBL] [Abstract][Full Text] [Related]
6. Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs.
Amirnasr A; Gits CMM; van Kuijk PF; Smid M; Vriends ALM; Rutkowski P; Sciot R; Schöffski P; Debiec-Rychter M; Sleijfer S; Wiemer EAC
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31238586
[TBL] [Abstract][Full Text] [Related]
7. Measuring Tumour Imatinib Concentrations in Gastrointestinal Stromal Tumours: Relevant or Redundant?
Giraud EL; de Jong LAW; van den Hombergh E; Kaal SEJ; van Erp NP; Desar IME
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296838
[TBL] [Abstract][Full Text] [Related]
8. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
9. Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.
Zook P; Pathak HB; Belinsky MG; Gersz L; Devarajan K; Zhou Y; Godwin AK; von Mehren M; Rink L
Clin Cancer Res; 2017 Jan; 23(1):171-180. PubMed ID: 27370604
[TBL] [Abstract][Full Text] [Related]
10. Identification of Novel Imatinib-Resistant Genes in Gastrointestinal Stromal Tumors.
Cao L; Zheng K; Liu Y; Song P; Wang C; Wang H; Wang N; Zhang S; Zhao Y
Front Genet; 2022; 13():878145. PubMed ID: 35646090
[TBL] [Abstract][Full Text] [Related]
11. [Establishment and pathologic analysis of imatinib-resistant gastrointestinal stromal tumor xenografts].
Zheng S; Wang XJ; Jia J; Pan YL; Tao DY; Lu HS; Huang KE
Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):176-80. PubMed ID: 22800481
[TBL] [Abstract][Full Text] [Related]
12. Integrated Transcriptome and Metabolomic Analysis Reveal Anti-Angiogenic Properties of Disarib, a Novel Bcl2-Specific Inhibitor.
Manjunath M; Swaroop S; Pradhan SS; Rao K R; Mahadeva R; Sivaramakrishnan V; Choudhary B
Genes (Basel); 2022 Jul; 13(7):. PubMed ID: 35885991
[TBL] [Abstract][Full Text] [Related]
13. Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors.
Hsueh YS; Chang HH; Shan YS; Sun HS; Fletcher JA; Li CF; Chen LT
Oncogene; 2019 Sep; 38(38):6550-6565. PubMed ID: 31363162
[TBL] [Abstract][Full Text] [Related]
14. Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors.
Lu X; Pang Y; Cao H; Liu X; Tu L; Shen Y; Jia X; Lee JC; Wang Y
Cancer Res; 2021 May; 81(9):2481-2494. PubMed ID: 33727226
[TBL] [Abstract][Full Text] [Related]
15. Establishment of the prediction model and biological mechanism exploration for secondary imatinib-resistant in gastrointestinal stromal tumor.
Wang C; Shen Z; Jiang K; Gao Z; Ye Y
Scand J Gastroenterol; 2022 Nov; 57(11):1334-1343. PubMed ID: 35723035
[TBL] [Abstract][Full Text] [Related]
16. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
17. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.
Akçakaya P; Caramuta S; Åhlen J; Ghaderi M; Berglund E; Östman A; Bränström R; Larsson C; Lui WO
Br J Cancer; 2014 Nov; 111(11):2091-102. PubMed ID: 25349971
[TBL] [Abstract][Full Text] [Related]
18. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
[TBL] [Abstract][Full Text] [Related]
19. Imatinib treatment for gastrointestinal stromal tumour (GIST).
Lopes LF; Bacchi CE
J Cell Mol Med; 2010 Jan; 14(1-2):42-50. PubMed ID: 19968734
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
